LenioBio GmbH, a Dusseldorf, Germany-based life sciences biotech offering protein manufacturing technology, called ALiCE, closed its Series-A Extension round with a total investment volume of €11.5m.
The round was led by current investor Bridford Group.
The company intends to use the funds to accelerate its continuous efforts in research and development of the ALiCE technology, process improvement of large-scale manufacturing and mapping of the various market opportunities.
Led by Dr. Remberto Martis, CEO, LenioBio is a protein expression platform company committed to the advancement of transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.
LenioBio was established as a legal entity in Germany in September 2016, with offices in Dusseldorf and R&D and production labs in Aachen.
Along with the investment round, LenioBio strengthened its Non-executive Board of Directors. New Board members include Dr. Remberto Martis, founder and CEO, Thomas Harding, Leopoldo Zambeletti and Karen Fallen.
FinSMEs
07/03/2022